Galapagos raises $300M on the back of first PhIII filgotinib success; Incyte pushes into PhIII with topical Jakafi

→ Galapagos$GLPG wasn’t about to let the success of its first Phase III for filgotinib — handled by lead partner Gilead — go by without a quick raise. The biotech garnered $300 million from the sale of its stock.

→ Incyte$INCY says its Phase IIb study for a cream formulation of Jakafi (ruxolitinib) produced promising results for patients with atopic dermatitis. Researchers are now moving ahead with a Phase III registration program.

→ Principia BioPharma is now boosting the size of its proposed IPO. The South San Francisci-based biotech wants to sell 6.3 million shares at a price range of $15 to $17.

→ VistaGen Therapeutics$VTGN issued a little more than $2 million in shares to Pheron Pharmaceuticals in exchange for rights to a drug for social anxiety disorder.

Sign in to Endpoints News

Request a magic link

Enter your email below to get a Magic link which lets you sign in quickly without using a password.Please note the Magic link is one-time use only and valid for only 24 hours.
Email:

← Go back

Set a new password

We will send you a link, with which you will be able to set a new password.Please note this link is for one-time use only and valid for only 24 hours.
Email:

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 33,800+ biopharma executives who read Endpoints News every day.